Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2004 1
2005 3
2006 3
2007 3
2008 4
2009 3
2010 3
2011 5
2012 3
2013 6
2014 4
2015 6
2016 5
2017 1
2018 6
2019 5
2020 3
2021 4
2022 3
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Results by year

Filters applied: . Clear all
Page 1
Chronic cholesterol administration to the brain supports complete and long-lasting cognitive and motor amelioration in Huntington's disease.
Birolini G, Valenza M, Ottonelli I, Talpo F, Minoli L, Cappelleri A, Bombaci M, Caccia C, Canevari C, Trucco A, Leoni V, Passoni A, Favagrossa M, Nucera MR, Colombo L, Paltrinieri S, Bagnati R, Duskey JT, Caraffi R, Vandelli MA, Taroni F, Salmona M, Scanziani E, Biella G, Ruozi B, Tosi G, Cattaneo E. Birolini G, et al. Among authors: bagnati r. Pharmacol Res. 2023 Aug;194:106823. doi: 10.1016/j.phrs.2023.106823. Epub 2023 Jun 17. Pharmacol Res. 2023. PMID: 37336430 Free PMC article.
Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations (Treat_CCM): a randomised, open-label, blinded-endpoint, phase 2 pilot trial.
Lanfranconi S, Scola E, Meessen JMTA, Pallini R, Bertani GA, Al-Shahi Salman R, Dejana E, Latini R; Treat_CCM Investigators. Lanfranconi S, et al. Lancet Neurol. 2023 Jan;22(1):35-44. doi: 10.1016/S1474-4422(22)00409-4. Epub 2022 Nov 17. Lancet Neurol. 2023. PMID: 36403580 Free article. Clinical Trial.
New aldo-keto reductase 1C3 (AKR1C3) inhibitors based on the hydroxytriazole scaffold.
Pippione AC, Kilic-Kurt Z, Kovachka S, Sainas S, Rolando B, Denasio E, Pors K, Adinolfi S, Zonari D, Bagnati R, Lolli ML, Spyrakis F, Oliaro-Bosso S, Boschi D. Pippione AC, et al. Among authors: bagnati r. Eur J Med Chem. 2022 Jul 5;237:114366. doi: 10.1016/j.ejmech.2022.114366. Epub 2022 Apr 13. Eur J Med Chem. 2022. PMID: 35447434 Free article.
Bioisosteres of Indomethacin as Inhibitors of Aldo-Keto Reductase 1C3.
Lolli ML, Carnovale IM, Pippione AC, Wahlgren WY, Bonanni D, Marini E, Zonari D, Gallicchio M, Boscaro V, Goyal P, Friemann R, Rolando B, Bagnati R, Adinolfi S, Oliaro-Bosso S, Boschi D. Lolli ML, et al. Among authors: bagnati r. ACS Med Chem Lett. 2019 Jan 28;10(4):437-443. doi: 10.1021/acsmedchemlett.8b00484. eCollection 2019 Apr 11. ACS Med Chem Lett. 2019. PMID: 30996776 Free PMC article.
Mouse aldehyde-oxidase-4 controls diurnal rhythms, fat deposition and locomotor activity.
Terao M, Barzago MM, Kurosaki M, Fratelli M, Bolis M, Borsotti A, Bigini P, Micotti E, Carli M, Invernizzi RW, Bagnati R, Passoni A, Pastorelli R, Brunelli L, Toschi I, Cesari V, Sanoh S, Garattini E. Terao M, et al. Among authors: bagnati r. Sci Rep. 2016 Jul 26;6:30343. doi: 10.1038/srep30343. Sci Rep. 2016. PMID: 27456060 Free PMC article.
70 results